India markets open in 8 hours 8 minutes

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.62-0.51 (-2.09%)
As of 3:36PM EDT. Market open.

Arcutis Biotherapeutics, Inc.

3027 Townsgate Road
Suite 300
Westlake Village, CA 91361
United States
805 418 5006
http://www.arcutis.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees75

Key executives

NameTitlePayExercisedYear born
Mr. Todd Franklin WatanabePres, CEO & Director734.63kN/A1968
Dr. Bhaskar Chaudhuri Ph.D.Co-Founder & Independent Director50.42kN/A1955
Mr. Kenneth A. LockChief Commercial Officer514.28kN/A1974
Dr. Patrick E. Burnett M.D., Ph.D.Sr. VP & Chief Medical Officer619.79kN/A1972
Mr. Scott L. BurrowsCFO & Principal Accounting OfficerN/AN/A1977
Ms. Patricia A. TurneySr. VP of OperationsN/AN/A1967
Dr. David W. OsborneChief Technical OfficerN/AN/A1961
Mr. Rajvir MadanChief Digital & Information OfficerN/AN/AN/A
Mr. Keith L. KleinGen. Counsel & Sec.N/AN/A1964
Ms. Courtney BartonChief Compliance Officer, VP, Chief of Staff & Chief Privacy OfficerN/AN/A1983
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Corporate governance

Arcutis Biotherapeutics, Inc.’s ISS governance QualityScore as of 1 July 2021 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.